MARKET

BIAF

BIAF

bioAffinity Tech
NASDAQ
0.2882
+0.0118
+4.27%
After Hours: 0.2984 +0.0102 +3.54% 17:58 03/24 EDT
OPEN
0.2800
PREV CLOSE
0.2764
HIGH
0.2940
LOW
0.2650
VOLUME
139.19K
TURNOVER
--
52 WEEK HIGH
3.163
52 WEEK LOW
0.2505
MARKET CAP
4.49M
P/E (TTM)
-0.3607
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at BIAF last week (0317-0321)?
Weekly Report · 1d ago
BioAffinity Technologies Announces CyPath Lung Study Identifying Breast Cancer Recurrence In 80-Year-Old, Highlighting Oncological Care Potential
Benzinga · 6d ago
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Benzinga · 03/18 12:07
12 Health Care Stocks Moving In Monday's Intraday Session
Benzinga · 03/17 17:05
Weekly Report: what happened at BIAF last week (0310-0314)?
Weekly Report · 03/17 11:03
Weekly Report: what happened at BIAF last week (0303-0307)?
Weekly Report · 03/10 11:05
bioAffinity Technologies Announces Targeted Strategic Actions To Improve Financial Performance And Accelerate The Commercial Growth Of CyPath Lung; Expects These Measures To Deliver ~$4M In Annual Cost Savings
Benzinga · 03/06 13:47
BioAffinity accelerates CyPath Lung amid $4M in annual cost savings at PPLS
TipRanks · 03/06 13:31
More
About BIAF
bioAffinity Technologies, Inc. is a biotechnology company focused on commercializing noninvasive tests for the detection of early-stage cancer and lung disease. The Company addresses the need for noninvasive diagnosis of early-stage cancer and diseases of the lung and broad-spectrum cancer treatment. Its segments include Diagnostic Research and Development (R&D) and Laboratory Services. Its Diagnostic R&D segment includes research and development and clinical development on diagnostic tests. Its Laboratory services include all the operations of Village Oaks and PPLS, in addition to sales and marketing of CyPath Lung from bioAffinity. Its first product, CyPath Lung, addresses the need for noninvasive detection of early-stage lung cancer. The CyPath Lung test enables physicians to more confidently identify patients who will likely benefit from timely intervention and more invasive follow-up procedures and those who are likely without lung cancer and should continue routine screening.

Webull offers bioAffinity Technologies Inc stock information, including NASDAQ: BIAF real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, BIAF stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading BIAF stock methods without spending real money on the virtual paper trading platform.